Vergelijking
Lixisenatide vs. Pramlintid
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
320367-13-3
151126-32-8
Molecuulmassa
4858.5 g/mol
3949.4 g/mol
Halfwaardetijd
3 h
geen gegevens
Sequentie
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2geen gegevens
Werkingsmechanisme
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Pramlintid
Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
5
0
waarvan bij mensen
5
0
Geregistreerde effecten
3
2
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
1
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Lixisenatide and Pramlintid?
- Lixisenatide is classified as "Metabool", while Pramlintid is classified as "Metabool". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lixisenatide or Pramlintid?
- The highest available evidence level is "Humane RCT" for Lixisenatide and "Humane RCT" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lixisenatide and Pramlintid in Germany and the United States?
- Duitsland: Lixisenatide — Op recept, Pramlintid — Niet goedgekeurd. Verenigde Staten: Lixisenatide — Niet goedgekeurd, Pramlintid — Op recept. These are factual summaries with source and review date on the individual pages.